Risk Stratification of Nodal PTCL

Completed

• Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-negative

• Registration Number: NCT03040206
• Lead Sponsor: Chonbuk National University Hospital

Brief Summary

This study is to investigate the prognostic significance of enhanced International Prognostic Index (NCCN-IPI) and post-treatment PET results in patients with newly diagnosed nodal peripheral T-cell lymphoma (PTCL), and establish a risk stratification model for nodal PTCL patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01
• Study First Submitted: 2017-01-31
• Study First Submitted QC: 2017-02-01
• Study First Posted: 2017-02-02
• Primary Completion: 2017-06
• Study Completion: 2017-12
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-05
• Last Update Posted: 2019-08-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 405

Inclusion Criteria

• Patients diagnosed with nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative)
• Patients diagnosed with between January 1, 2004 and April 30, 2016
• initially treated with curative intent
• Patients with standard 18F-fluorodeoxyglucose (FDG) PET or PET-CT data at the time of diagnosis and at the end of primary treatment

Exclusion Criteria

• Patients diagnosed with extranodal PTCLs, including followings (extranodal NK/T-cell lymphoma, nasal type; enteropathy-associated T-cell lymphoma; hepatosplenic T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; EBV-positive T-cell lymphoproliferative childhood disorders, and primary cutaneous lymphomas)
• Patients with ALCL-ALK+
• Patients who do not have 18F-FDG PET or PET-CT data either at diagnosis or at the end of treatment available for review

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression-free survival	5 year	Time between the date of diagnosis and any kinds of death or disease relapse/progrression

Secondary Outcome Measures

Name	Time	Method
overall survival	5 year	Time between the date of diagnosis and any kinds of death

Trial Locations

Locations (1)

Chonbuk Nationla University Hospital; 🇰🇷 Jeonju, Korea, Republic of